TY - JOUR
T1 - Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease
AU - Wang, Xiao
AU - Xie, Liang
AU - Crane, Janet
AU - Zhen, Gehua
AU - Li, Fengfeng
AU - Yang, Ping
AU - Gao, Manman
AU - Deng, Ruoxian
AU - Wang, Yiguo
AU - Jia, Xiaohua
AU - Fan, Cunyi
AU - Wan, Mei
AU - Cao, Xu
N1 - Funding Information:
This work was supported in part by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases grants AR071432 and AR063943 (to XC).
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Enthesopathy is a disorder of bone, tendon, or ligament insertion. It represents one-fourth of all tendon-ligament diseases and is one of the most difficult tendon-ligament disorders to treat. Despite its high prevalence, the exact pathogenesis of this condition remains unknown. Here, we show that TGF-β was activated in both a semi-Achilles tendon transection (SMTS) mouse model and in a dorsiflexion immobilization (DI) mouse model of enthesopathy. High concentrations of active TGF-β recruited mesenchymal stromal stem cells (MSCs) and led to excessive vessel formation, bone deterioration, and fibrocartilage calcification. Transgenic expression of active TGF-β1 in bone also induced enthesopathy with a phenotype similar to that observed in SMTS and DI mice. Systemic inhibition of TGF-β activity by injection of 1D11, a TGF-β–neutralizing antibody, but not a vehicle antibody, attenuated the excessive vessel formation and restored uncoupled bone remodeling in SMTS mice. 1D11-treated SMTS fibrocartilage had increased proteoglycan and decreased collagen X and matrix metalloproteinase 13 expression relative to control antibody treatment. Notably, inducible knockout of the TGF-β type II receptor in mouse MSCs preserved the bone microarchitecture and fibrocartilage composition after SMTS relative to the WT littermate controls. Thus, elevated levels of active TGF-β in the enthesis bone marrow induce the initial pathological changes of enthesopathy, indicating that TGF-β inhibition could be a potential therapeutic strategy.
AB - Enthesopathy is a disorder of bone, tendon, or ligament insertion. It represents one-fourth of all tendon-ligament diseases and is one of the most difficult tendon-ligament disorders to treat. Despite its high prevalence, the exact pathogenesis of this condition remains unknown. Here, we show that TGF-β was activated in both a semi-Achilles tendon transection (SMTS) mouse model and in a dorsiflexion immobilization (DI) mouse model of enthesopathy. High concentrations of active TGF-β recruited mesenchymal stromal stem cells (MSCs) and led to excessive vessel formation, bone deterioration, and fibrocartilage calcification. Transgenic expression of active TGF-β1 in bone also induced enthesopathy with a phenotype similar to that observed in SMTS and DI mice. Systemic inhibition of TGF-β activity by injection of 1D11, a TGF-β–neutralizing antibody, but not a vehicle antibody, attenuated the excessive vessel formation and restored uncoupled bone remodeling in SMTS mice. 1D11-treated SMTS fibrocartilage had increased proteoglycan and decreased collagen X and matrix metalloproteinase 13 expression relative to control antibody treatment. Notably, inducible knockout of the TGF-β type II receptor in mouse MSCs preserved the bone microarchitecture and fibrocartilage composition after SMTS relative to the WT littermate controls. Thus, elevated levels of active TGF-β in the enthesis bone marrow induce the initial pathological changes of enthesopathy, indicating that TGF-β inhibition could be a potential therapeutic strategy.
UR - http://www.scopus.com/inward/record.url?scp=85041472995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041472995&partnerID=8YFLogxK
U2 - 10.1172/JCI96186
DO - 10.1172/JCI96186
M3 - Article
C2 - 29355842
AN - SCOPUS:85041472995
SN - 0021-9738
VL - 128
SP - 846
EP - 860
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -